Blood Pressure Alterations in CML Patients Treated with Imatinib vs. Nilotinib: A Clinical Insight

Chronic Myeloid Leukemia is a hematologic malignancy characterized by the BCR-ABL fusion gene. Tyrosine Kinase Inhibitors such as imatinib and nilotinib have significantly improved the prognosis for CML patients. However, prolonged TKI therapy is associated with cardiovascular side effects, particul...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Anwar Wardiyanti, Harjianti Tutik, Tandean Pendrik, Bakri Syakib, Hp Faridin, Zainuddin Andi Alfian
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Sciendo 2026-04-01
Serie:	Romanian Journal of Internal Medicine
Soggetti:	chronic myeloid leukemia (cml) tyrosine kinase inhibitors (tkis) blood pressure changes imatinib nilotinib
Accesso online:	https://doi.org/10.2478/rjim-2026-0005
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!